Special Issue

Antimicrobial-Resistant Pathogens Isolated from Animals and Their Products

Message from the Guest Editors

Antimicrobial resistance in pathogens isolated from animals and their products is a global concern in human medicine. Antimicrobial agents are used for food-producing animals for treating bacterial infections and as food additives for growth promotion. Although the use of antimicrobial agents has contributed to a stable supply of foods of animal origin, pathogens resistant to important antimicrobial agents for human medicine, such as fluoroquinolones and third-generation cephalosporins, have been isolated from animals and their products worldwide. To manage the risk of transmission of antimicrobial-resistant pathogens to the human population, the prevalence and characteristics of these pathogens in animals and their products should be investigated. The risk management options established by risk managers should be based on scientific data. More data are needed to established effective options. Authors are invited to submit articles describing not only antimicrobial-resistant pathogens in animals and their products, but also the effectiveness of risk management options at the farm level.

Guest Editors

Dr. Yoshimasa Sasaki

Division of Biomedical Food Research, National Institute of Health Sciences, Kawasaki, Japan

Prof. Dr. Tetsuo Asai

Department of Applied Veterinary Sciences United Graduate, School of Veterinary Sciences, Gifu, Japan

Deadline for manuscript submissions

closed (30 November 2021)

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed

mdpi.com/si/67492

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/antibiotics

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed

mdpi.com/journal/antibiotics

About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

MDPI